Prostate Cancer New Reference: Enzalutamide with Radium-223 for Prostate Cancer Ulas D. Bayraktar, MD 2025-06-02
Bladder Cancer New Reference: Enfortumab Vedotin + Pembrolizumab for Advanced Urothelial Carcinoma Ulas D. Bayraktar, MD 2025-06-02
Colorectal Cancer New Reference: Encorafenib, Cetuximab with FOLFOX for bRAF Mutated Metastatic Colorectal Cancer Ulas D. Bayraktar, MD 2025-06-02
Multiple Myeloma New Indication: Daratumumab for High-Risk Smoldering Myeloma Ulas D. Bayraktar, MD 2025-06-02
Bladder Cancer New Protocol: Maintenance Sacituzumab Govitecan with Avelumab for Urothelial Carcinoma Ulas D. Bayraktar, MD 2025-06-02
Non-Small Cell Lung Cancer New Reference: Maintenance Atezolizumab for Stage IB-IIIA NSCLC Ulas D. Bayraktar, MD 2025-06-02
Chronic Lymphocytic Leukemia New Protocol: Zanubrutinib with Venetoclax for Untreated CLL Ulas D. Bayraktar, MD 2025-06-02
Acute myeloid leukemia New Protocol: Venetoclax with Decitabine for AML Induction in Fit Patients Ulas D. Bayraktar, MD 2025-06-02
GastroEsophageal Cancer New Reference: Trastuzumab Deruxtecan for her2+ Gastric Cancer Ulas D. Bayraktar, MD 2025-06-02
